Paul S Schwartz

US Patent:

42062080, Jun 3, 1980

Filed:

Dec 22, 1978

Appl. No.:

5/972354

Inventors:

Glen R. Gale - Charleston SC
Paul Schwartz - Charleston SC

Assignee:

The United States of America as represented by the Department of Health,
Education and Welfare - Washington DC

International Classification:

A61K 31675
A61K 31505
A61K 3128

US Classification:

424200

Abstract:

##STR1## 4-Carboxyphthalato(1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5. degree. C. ) of the desired product which is preferably utilized as the alkali metal salt.

US Patent:

41372484, Jan 30, 1979

Filed:

Aug 29, 1977

Appl. No.:

5/828926

Inventors:

Glen R. Gale - Charleston SC
Paul Schwartz - Charleston SC

Assignee:

The United States of America as represented by the Department of Health,
Education and Welfare - Washington DC

International Classification:

C07F 1500

US Classification:

260429R

Abstract:

##STR1## 4-Carboxyphthalato (1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5. degree. C) of the desired product which is preferably utilized as the alkali metal salt.

US Patent:

42062071, Jun 3, 1980

Filed:

Dec 22, 1978

Appl. No.:

5/972338

Inventors:

Glen R. Gale - Charleston SC
Paul Schwartz - Charleston SC

Assignee:

The United States of America as represented by the Department of Health,
Education and Welfare - Washington DC

International Classification:

A61K 31675
A61K 3128

US Classification:

424200

Abstract:

##STR1## 4-Carboxyphthalato(1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5. degree. C. ) of the desired product which is preferably utilized as the alkali metal salt.

US Patent:

42062268, Jun 3, 1980

Filed:

Jul 19, 1978

Appl. No.:

5/926035

Inventors:

Glen R. Gale - Charleston SC
Paul Schwartz - Charleston SC

Assignee:

The United States of America as represented by the Department of Health,
Education and Welfare - Washington DC

International Classification:

A61K 3128

US Classification:

424287

Abstract:

##STR1## Y=H, alk met 4-Carboxyphthalato(1,2-diaminocyclohexane) platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane) platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5. degree. C. ) of the desired product which is preferably utilized as the alkali metal salt.

US Patent:

42028906, May 13, 1980

Filed:

Dec 22, 1978

Appl. No.:

5/972336

Inventors:

Glen R. Gale - Charleston SC
Paul Schwartz - Charleston SC

Assignee:

The United States of America as represented by the Department of Health,
Education and Welfare - Washington DC

International Classification:

A61K 31675
A61K 3128
A61K 3117

US Classification:

424200

Abstract:

##STR1## 4-Carboxyphthalato(1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5. degree. C. ) of the desired product which is preferably utilized as the alkali metal salt.

US Patent:

20180283319, Oct 4, 2018

Filed:

Oct 15, 2016

Appl. No.:

15/766813

Inventors:

- Stony Brook NY, US
Paul Schwartz - Woodbury NY, US
Peter Hofbauer - West Bloomfield MI, US
Adrian Tusinean - Windsor, CA

Assignee:

ThermoLift, Inc. - Stony Brook NY

International Classification:

F02G 1/055

Abstract:

A thermodynamic apparatus, such as a Stirling engine or a Vuilleumier heat pump, has a heat exchanger in which energy is exchanged between a working fluid and an exhaust gas stream. On top of the cylinder of the thermodynamic apparatus is a dome-shaped section. By incorporating the heat exchanger within the dome, the flow paths can be simplified, the number of separate components reduced, and overall weight reduced. Flow passages for the working fluid are embedded in the dome. Channels for the exhaust gases are formed in an outer surface. The passages and the channels are helically arranged, one clockwise and one counter clockwise. The dome can be cast with a core for the casting fabricated via three-dimensional printing. In some embodiments, the dome is made of fiber-reinforced material.